{"id":8140,"date":"2023-08-04T11:11:25","date_gmt":"2023-08-04T11:11:25","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8140"},"modified":"2023-08-04T11:11:26","modified_gmt":"2023-08-04T11:11:26","slug":"cd137-cd137l-pathway","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/cd137-cd137l-pathway\/","title":{"rendered":"CD137 \u2013 CD137L Pathway"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

CD137 (4-1BB; TNFRSF9) is an activating receptor binding to CD137L (4-1BBL; TNFSF9). Because CD137 is expressed on both natural killer (NK) cells and T cells, it can trigger both innate and adaptive immunity. After these cells have been activated by exposure to tumour antigen, CD137 signals stimulate them to reproduce and generate antitumour activity. CD137 has been shown to play a critical role on T cells in the development of immune memory and the creation of a durable immune response. On lymphocytes, the presence of CD137 appears to be a marker for tumour reactivity. Activation of CD137 signalling can stimulate both cytotoxic T cell and NK cell activity.<\/p>\n\n\n\n

LIT:<\/strong>\u00a0\u00a04-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy: D.S. Vinay & B.S. Kwon; BMB Rep.\u00a047,<\/strong>\u00a0122 (2014) \u2022 CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses: B. Dharmadhikari, et al.; Oncoimmunology\u00a05,<\/strong>\u00a0e1113367 (2015)<\/p>\n\n\n\n

Biologically Active\u00a0CD137 and CD137L Proteins<\/strong><\/p>\n\n\n\n

See all Biologically Active\u00a0CD137 and CD137L Proteins by AdipoGen Life Sciences\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD137 and CD137L Proteins by Chimerigen\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD137 and CD137L Proteins by Ancell\u00a0here<\/a>.<\/p>\n\n\n\n

VALIDATED\u00a0Antibodies for CD137 and CD137L Research<\/strong><\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for CD137 and CD137L Research by AdipoGen Life Sciences here<\/a>.<\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for CD137 and CD137L Research by Ancell here<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on adipogen.com\/cd137-cd137l-pathway\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

CD137 is an activating receptor binding to CD137L, expressed on natural killer (NK) cells & T cells, therefore triggering innate & adaptive immunity.<\/p>\n","protected":false},"author":13,"featured_media":8143,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,185,7,683,685],"class_list":["post-8140","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-antibodies","tag-cancer","tag-proteins","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8140"}],"version-history":[{"count":2,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8140\/revisions"}],"predecessor-version":[{"id":8144,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8140\/revisions\/8144"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8143"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}